
Serge Belanger
Stock Analyst at Needham
(4.62)
# 932
Out of 5,144 analysts
990
Total ratings
45.2%
Success rate
10.8%
Average return
Main Sectors:
Stocks Rated by Serge Belanger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Reiterated: Hold | n/a | $3.20 | - | 50 | Nov 13, 2026 | |
| CRMD CorMedix | Reiterated: Buy | $15 → $14 | $4.82 | +190.46% | 37 | Nov 10, 2026 | |
| OCUL Ocular Therapeutix | Reiterated: Buy | $18 | $6.01 | +199.50% | 18 | Nov 10, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $23 | $13.29 | +73.06% | 53 | Nov 10, 2026 | |
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $60 | $39.26 | +52.83% | 42 | Nov 10, 2026 | |
| LQDA Liquidia | Reiterated: Buy | $72 → $58 | $56.37 | +2.89% | 74 | Oct 14, 2026 | |
| PCRX Pacira BioSciences | Downgraded: Hold | n/a | $36.48 | - | 83 | Oct 8, 2026 | |
| CYTK Cytokinetics | Reiterated: Buy | $112 | $53.17 | +110.65% | 55 | Oct 5, 2026 | |
| EVMN Evommune | Reiterated: Buy | $28 | $7.10 | +294.37% | 2 | Sep 9, 2026 | |
| BCRX BioCryst Pharmaceuticals | Reiterated: Buy | $16 | $7.45 | +114.77% | 59 | Sep 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $16.68 | - | 55 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $164 | $128.05 | +28.07% | 3 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.2843 | - | 62 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $11.73 | +155.75% | 26 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 | $29.17 | -31.44% | 45 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $19.46 | +146.66% | 18 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 | $7.63 | +398.03% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $36 → $40 | $27.15 | +47.33% | 35 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56 → $46 | $25.43 | +80.89% | 168 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $6.63 | - | 31 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $29.80 | +14.09% | 36 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.4486 | n/a | 9 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.19 | n/a | 13 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $0.8587 | n/a | 1 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.00605 | n/a | 2 | Jun 26, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $5 | $0.0708 | n/a | 3 | Aug 19, 2016 |
Verrica Pharmaceuticals
Nov 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.20
Upside: -
CorMedix
Nov 10, 2026
Reiterated: Buy
Price Target: $15 → $14
Current: $4.82
Upside: +190.46%
Ocular Therapeutix
Nov 10, 2026
Reiterated: Buy
Price Target: $18
Current: $6.01
Upside: +199.50%
Trevi Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $23
Current: $13.29
Upside: +73.06%
Xenon Pharmaceuticals
Nov 10, 2026
Reiterated: Buy
Price Target: $60
Current: $39.26
Upside: +52.83%
Liquidia
Oct 14, 2026
Reiterated: Buy
Price Target: $72 → $58
Current: $56.37
Upside: +2.89%
Pacira BioSciences
Oct 8, 2026
Downgraded: Hold
Price Target: n/a
Current: $36.48
Upside: -
Cytokinetics
Oct 5, 2026
Reiterated: Buy
Price Target: $112
Current: $53.17
Upside: +110.65%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $28
Current: $7.10
Upside: +294.37%
BioCryst Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $16
Current: $7.45
Upside: +114.77%
Aug 13, 2026
Reiterated: Hold
Price Target: n/a
Current: $16.68
Upside: -
Aug 12, 2026
Reiterated: Buy
Price Target: $164
Current: $128.05
Upside: +28.07%
Aug 10, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.2843
Upside: -
Aug 10, 2026
Reiterated: Buy
Price Target: $30
Current: $11.73
Upside: +155.75%
Aug 7, 2026
Reiterated: Hold
Price Target: $20
Current: $29.17
Upside: -31.44%
Aug 7, 2026
Reiterated: Buy
Price Target: $48
Current: $19.46
Upside: +146.66%
Aug 7, 2026
Reiterated: Buy
Price Target: $38
Current: $7.63
Upside: +398.03%
Aug 6, 2026
Rated: Buy
Price Target: $36 → $40
Current: $27.15
Upside: +47.33%
Aug 6, 2026
Reiterated: Buy
Price Target: $56 → $46
Current: $25.43
Upside: +80.89%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $6.63
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $34
Current: $29.80
Upside: +14.09%
Oct 28, 2022
Rated: Hold
Price Target: n/a
Current: $0.4486
Upside: n/a
Oct 28, 2022
Rated: Hold
Price Target: n/a
Current: $1.19
Upside: n/a
Nov 5, 2021
Reiterated: Buy
Price Target: $22
Current: $0.8587
Upside: n/a
Jun 26, 2017
Reiterated: Hold
Price Target: n/a
Current: $0.00605
Upside: n/a
Aug 19, 2016
Reiterated: Buy
Price Target: $11 → $5
Current: $0.0708
Upside: n/a